Development of oral cancer treatment by hyperthermia generated with contrast agent Resovist and Cetuximab
Project/Area Number |
26463053
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Surgical dentistry
|
Research Institution | Yokohama City University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
來生 知 横浜市立大学, 医学部, 准教授 (30545059)
藤内 祝 横浜市立大学, 医学研究科, 教授 (50172127)
光藤 健司 横浜市立大学, 医学部, 准教授 (70303641)
|
Project Period (FY) |
2014-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | 口腔癌 / ハイパーサーミア / セツキシマブ / 交流磁場 / 温熱 / 分子標的薬 / 温熱療法 / 磁性体ナノ粒子 |
Outline of Final Research Achievements |
The purpose of this study is the development of a new treatment for oral cancer indicating the resistance for the anticancer effect of cetuximab by using hyperthermia generated with contrast agent Resovist in an alternating magnetic field(AMF) and Cetuximab.We found that the expression of EGFR in human oral squamous cell carcinoma cells increased by thermal stimulation.Therefore, we thought that the sensitivity of Cetuximab-resistant human oral squamous cell carcinoma cells for cetuximab can be activated by thermal stimulation-induced high expression of EGFR.As a result of the study using mouse models based on this speculation, the anti-cancer effect were observed in the group treated with combination of cetuximab and hyperthermia generated with contrast agent Resovist in AMF.
|
Report
(5 results)
Research Products
(15 results)
-
[Journal Article] Treatment of oral cancer using magnetized paclitaxel2018
Author(s)
Nakakaji Rina、Umemura Masanari、Mitsudo Kenji、Kim Jeong-Hwan、Hoshino Yujiro、Sato Itaru、Masuda Takatsugu、Yamamoto Masahiro、Kioi Mitomu、Koizumi Toshiyuki、Fujita Takayuki、Yokoyama Utako、Iida Masaki、Sato Motohiko、以下7名
-
Journal Title
Oncotarget
Volume: 9
Issue: 21
Pages: 15591-15605
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80?years old2017
Author(s)
Hayashi Y, Mitsudo K, Sakuma K, Iida M, Iwai T, Nakashima H, Okamoto Y, Koizumi T, Oguri S, Hirota M, Kioi M, Koike I, Hata M, Tohnai I.
-
Journal Title
Radiation Oncology
Volume: 12
Issue: 1
Pages: 112-112
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
[Presentation] Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: Analysis of therapeutic results in 112 cases.2017
Author(s)
Mitsudo K, Koizumi T, Hayashi Y, Sugiura K, Iida M, Iwai T, Nakashima H, Oguri S, Kioi M, Hirota M, Tohnai I
Organizer
6th World Oral Cancer Congress of the International Academy of Oral Oncology
Related Report
Int'l Joint Research
-
-
-
[Presentation] Organ preservation with daily concurrent chemoradiotherapy using retrograde superselective intra-arterial infusion for locally advanced tongue cancer: analysis of therapeutic results in 101 cases.2016
Author(s)
7.Mitsudo K, Oguri S, Minamiyama S, Iida M, Iwai T, Nakashima H, Koizumi T, Kioi M, Hirota M, Tohnai I
Organizer
2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Place of Presentation
Chicago,USA
Year and Date
2016-06-03
Related Report
Int'l Joint Research
-
[Presentation] A case report of thermobiochemoradiation therapy using superselective intra-arterial infusion for carcinoma of the buccal mucosa with N3 lymph node metastases.2016
Author(s)
1.Toshiyuki Koizumi, Kenji Mitsudo, Masaki Iida, Hideyuki Nakashima, Jun Ueda, Senri Oguri, Toshinori Iwai, Makoto Hirota, Mitomu Kioi, Iwai Tohnai
Organizer
The 12th International congress of hyperthermic oncology
Place of Presentation
New Orleans, USA
Year and Date
2016-04-11
Related Report
Int'l Joint Research
-
-
-
-